<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83419">
  <stage>Registered</stage>
  <submitdate>3/12/2008</submitdate>
  <approvaldate>3/12/2008</approvaldate>
  <actrnumber>ACTRN12608000603314</actrnumber>
  <trial_identification>
    <studytitle>An Open-Label, Dose Escalation Study of the Safety and Tolerability of 20089 (Triamcinolone Acetonide Intravitreal Injection) in the Treatment of Patients with Cystoid Macular Edema Associated with Retinal Vein Occlusion or Cataract Surgery</studytitle>
    <scientifictitle>An Open-Label, Dose Escalation Study of the Safety and Tolerability of 20089 (Triamcinolone Acetonide Intravitreal Injection) in the Treatment of Patients with Cystoid Macular Edema Associated with Retinal Vein Occlusion or Cataract Surgery</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Cystoid Macular Edema</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intravitreal injection of extended release triamcinolone acetonide for treatment of macular edema.  Each patient will receive only one injection.  The first cohort of five patients will all receive the 6.9 mg injection.  The second cohort of five patients will receive the 13.8 mg injection.</interventions>
    <comparator>No control group.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety of drug in the eye at Day 60 timepoint as measured by intraocular pressure rise, slit lamp examination for anterior chamber cells and flare, presence of cataract, infection, hemorrhage or retinal detachment.</outcome>
      <timepoint>1 day, 7 days, 30 days, 60 days, 120 days, 180 days, 270 days, 360 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>reduction of macular edema as measured by optical coherence tomography</outcome>
      <timepoint>1 day, 7 days, 30 days, 60 days, 120 days, 180 days, 270 days, 360 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Cystoid Macular Edema associated with retinal vein occlusion or post cataract surgery</inclusivecriteria>
    <inclusiveminage>45</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Visual acuity not likely to be improved by treatment; recent treatment by other intravitreal therapies or laser therapy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>11/05/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>CA</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Icon Bioscience</primarysponsorname>
    <primarysponsoraddress>1253 Reamwood Ave.
Sunnyvale, CA 94089
USA</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Icon Bioscience</fundingname>
      <fundingaddress>1253 Reamwood Ave.
Sunnyvale, CA 94089
USA</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to test the safety and tolerability of a extended duration drug delivery system for the eye.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Western Institutional Review Board</ethicname>
      <ethicaddress>Western Institutional Review Board
3535 7th Ave. S.W.
PO Box 12029
Olympia, WA 98508</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>9/06/2007</ethicsubmitdate>
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>W. Sandy White</name>
      <address>1253 Reamwood Ave.
Sunnyvale, CA 94089</address>
      <phone>+1 408-734-8188</phone>
      <fax />
      <email>info@iconbioscience.</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>W. Sandy White</name>
      <address>1253 Reamwood Ave.
Sunnyvale, CA 94089</address>
      <phone>+1 408-734-8188</phone>
      <fax />
      <email>info@iconbioscience.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>D. Y. Hung</name>
      <address>1253 Reamwood Ave
Sunnyvale, CA 94089</address>
      <phone>+1 408-734-8188</phone>
      <fax />
      <email>deanhung@iconbioscience.com</email>
      <country>United States of America</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>